Roche discontinues Genmab cancer drug
This article was originally published in Scrip
Executive Summary
Roche has discontinued development of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor, RG1507, which was the most advanced product it was developing in collaboration with Genmab for various cancers.